Amy Reilly
Investor Relations Contact chez DYNE THERAPEUTICS, INC.
Profil
Amy Reilly is currently the Head of Corporate Communication & Investor Relations at Dyne Therapeutics, Inc. She previously worked as the Director of Corporate Communications at ImmunoGen, Inc. from 2015 to 2017.
Prior to that, she was the Director of Employee Communications & Philanthropy at Cubist Pharmaceuticals LLC from 2013 to 2015.
In 2017, she briefly served as the Senior Director of Internal Communications at Thermo Fisher Scientific, Inc. From 2018 to 2020, she held the position of Vice President of Communications & Investor Relations at Kaleido Biosciences, Inc. Ms. Reilly completed her undergraduate degree at Bowdoin College.
Postes actifs de Amy Reilly
| Sociétés | Poste | Début |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Investor Relations Contact | 01/07/2020 |
Anciens postes connus de Amy Reilly
| Sociétés | Poste | Fin |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Investor Relations Contact | 01/05/2020 |
| THERMO FISHER SCIENTIFIC | Public Communications Contact | 01/10/2017 |
| IMMUNOGEN, INC. | Public Communications Contact | 01/03/2017 |
| CUBIST PHARMACEUTICALS INC | Public Communications Contact | 01/01/2015 |
Formation de Amy Reilly
| Bowdoin College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| THERMO FISHER SCIENTIFIC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
